Parkinson's Disease Neuroprotection Clinical Centers

帕金森病神经保护临床中心

• 批准号: 6659055
• 负责人: JOHN FANG
• 金额: $ 11.14万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6659055
• 关键词: Parkinson's disease; chemoprevention; clinical research; clinical trials; cooperative study; human subject; human therapy evaluation; nervous system disorder therapy; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): As outlined in this RFA (RFA-NS-02-010) announcement, the aims of this project are to create a clinical center for the conduct of future clinical trials of neuroprotection for Parkinson's disease. This site has three board-certified neurologists trained in movement disorders who will participate in this proposed project. Upon implementation of this project these neurologists will collaborate to conduct a pilot trial of an agent to prevent disease progression in PD. Subsequently, additional collaboration with the other clinical center sites will lead to at least one multicenter trial. This project will help to maintain a stable infrastructure for the administration of the clinical trial(s) in neuroprotection related to Parkinson's disease. In addition, the conduct of this type of clinical trial(s) will generate a sample of patients with early PD who may be willing to participate in genetic studies. Similarly, subjects may be willing to participate in studies to identify markers from blood or cerebrospinal fluid that may indicate disease presence or severity. This research may lead to a greater understanding of PD and better treatments.

描述（由申请人提供）：如本RFA（RFA-NS-02-010）公告所述，本项目的目的是创建一个临床中心，用于开展未来帕金森病神经保护临床试验。该研究中心有三名接受过运动障碍培训的委员会认证的神经科医生，他们将参与该拟议项目。在实施该项目后，这些神经科医生将合作进行一项预防PD疾病进展的药物的试点试验。随后，与其他临床中心的额外合作将导致至少一项多中心试验。 该项目将有助于维持一个稳定的基础设施，用于管理帕金森病相关神经保护的临床试验。此外，此类临床试验的开展将产生可能愿意参与遗传学研究的早期PD患者样本。同样，受试者可能愿意参与研究，以确定血液或脑脊液中可能指示疾病存在或严重程度的标志物。这项研究可能会导致更好地了解PD和更好的治疗。